2 days ago
@yahoofinaceBefore the agreement with Mesoblast, Grünenthal redefined the realignment of the research and development organization. Cell and gene therapy is laid down as a core competence. The entire research and development department has been heavily restructured, which also involves layoffs. If I interpret this correctly, there is no doubt about the success of cell therapy at Grünenthal - neither do we as Meso shareholders!
https://www.grunenthal.com/en/press-room/view-press-release?pressReleaseId=3098e512-9967-4186-a2dc-26122cfa6b6e
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA, page-40
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 99.5¢ | 96.5¢ | $1.393M | 1.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 12709 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.5¢ | 43746 | 15 |
View Market Depth
| Last trade - 12.49pm 26/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |